Relmada Therapeutics (RLMD) Long-Term Debt Repayments (2014 - 2020)
Relmada Therapeutics (RLMD) reported Long-Term Debt Repayments of $110247.0 for Q1 2020, up 28.24% year-over-year from $85969.0 in Q2 2019, and down 56.59% on a QoQ basis from $253957.0 in Q4 2019.
Relmada Therapeutics (RLMD) has 7 years of Long-Term Debt Repayments data on file, last reported at $110247.0 in Q1 2020.
- Quarterly Long-Term Debt Repayments rose 28.24% year-over-year to $110247.0 in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $110247.0 (down 77.25% YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
- Long-Term Debt Repayments retreated to $110247.0 in Q1 2020 per RLMD's latest filing, from $253957.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $253957.0 in Q4 2019 and bottomed at $27583.0 in Q2 2017.
- The 5-year median for Long-Term Debt Repayments is $84966.0 (2018), against an average of $91750.5.
- The widest annual swing landed in 2016, when Long-Term Debt Repayments slumped 38.12%; it then soared 197.14% in 2019.
- Tracing RLMD's Long-Term Debt Repayments over 5 years: stood at $54403.0 in 2016, then surged by 52.43% to $82929.0 in 2017, then increased by 3.06% to $85466.0 in 2018, then soared by 197.14% to $253957.0 in 2019, then tumbled by 56.59% to $110247.0 in 2020.
- Per Business Quant, the three latest RLMD Long-Term Debt Repayments figures stand at $110247.0 (Q1 2020), $253957.0 (Q4 2019), and $108279.0 (Q3 2019).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 110,247.00 |
| Mar 31, 2020 | 110,247.00 |
| Dec 31, 2019 | 253,957.00 |
| Dec 31, 2019 | 253,957.00 |
| Sep 30, 2019 | 108,279.00 |
| Sep 30, 2019 | 108,279.00 |
| Jun 30, 2019 | 36,380.00 |
| Jun 30, 2019 | 36,380.00 |
| Mar 31, 2019 | 85,969.00 |
| Mar 31, 2019 | 85,969.00 |
| Dec 31, 2018 | 85,466.00 |
| Dec 31, 2018 | 85,466.00 |
| Sep 30, 2018 | 84,966.00 |
| Sep 30, 2018 | 84,966.00 |
| Mar 31, 2018 | 83,355.00 |
| Mar 31, 2018 | 83,355.00 |
| Dec 31, 2017 | 82,929.00 |
| Dec 31, 2017 | 82,929.00 |
| Sep 30, 2017 | 82,506.00 |
| Sep 30, 2017 | 82,506.00 |
| Jun 30, 2017 | 27,583.00 |
| Jun 30, 2017 | 27,583.00 |
| Mar 31, 2017 | 82,450.00 |
| Mar 31, 2017 | 82,450.00 |
| Dec 31, 2016 | 54,403.00 |
| Dec 31, 2016 | 54,403.00 |
| Sep 30, 2016 | 109,234.00 |
| Sep 30, 2016 | 109,234.00 |
| Mar 31, 2016 | 88,533.00 |
| Mar 31, 2016 | 88,533.00 |
| Dec 31, 2015 | 87,915.00 |
| Dec 31, 2015 | 87,915.00 |
| Sep 30, 2015 | 87,304.00 |
| Sep 30, 2015 | 87,304.00 |
| Jun 30, 2015 | -1.00 |
| Jun 30, 2015 | -1.00 |
| Mar 31, 2015 | 38,089.00 |
| Mar 31, 2015 | 38,089.00 |
| Dec 31, 2014 | 107,096.00 |
| Dec 31, 2014 | 107,096.00 |
| Sep 30, 2014 | 148,441.00 |
| Sep 30, 2014 | 148,441.00 |
| Jun 30, 2014 | 19,493.00 |
| Jun 30, 2014 | 19,493.00 |